Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss medication Wegovy. Experts say an oral medication for weight loss might be more cost effective and easier for people to use.

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage candidates developed by Septerna.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.